Latest News
Latest News
Pediatric psoriasis: Black children, males more likely to have palmoplantar subtype, study finds
Nail involvement occurred in significantly more Black and Hispanic/Latino patients than in White patients.
From the Journals
Anemia, iron deficit common in rheumatic disease pregnancy
Low maternal levels of hemoglobin and serum ferritin in pregnancy were associated with adverse infant outcomes.
From the Journals
Anti-acid meds lower strength of systemic sclerosis drug
Weakened bioavailability of mycophenolate mofetil could require adjustments in treatment.
Conference Coverage
Are women and men with rheumatism treated equally?
Compared with men, women receive a diagnosis of rheumatic disease much later and are treated more poorly, research suggests.
News from the FDA/CDC
Intravenous formulation of secukinumab gets FDA approval
This new route of administration is expected to become available during the fourth quarter of 2023.
Latest News
Growing ‘tranq’ threat poses challenges for PCPs
“Xylazine is making the deadliest drug threat our country has ever faced, fentanyl, even deadlier.”
From the Journals
Adverse event rates compared for colchicine, NSAIDs when starting allopurinol for gout
Patients receiving prophylactic colchicine or NSAIDs with initiation of allopurinol for gout have more adverse events than those who receive no...
From the Journals
More evidence shows COVID-19’s link to risk for autoimmune disease
Patients with more severe COVID-19 that required hospitalization in the ICU were more likely to develop vasculitis, alopecia totalis, and several...
Latest News
Choosing which biologic to prescribe for psoriasis
In cases of primary failure, consider revisiting the diagnosis, Dr. April Armstrong advised.
Latest News
FDA approves topical roflumilast for psoriasis in children aged 6-11
Topical roflumilast was first approved in July 2022 for individuals aged 12 and older.
News from the FDA/CDC
FDA approves ninth Humira biosimilar, with interchangeability
The drug, adalimumab-afzb (Abrilada), is the second adalimumab biosimilar approved with interchangeability status. It will be available in late...